Posted by Michael Wonder on 19 May 2026
FDA approves Immgolis (golimumab-sldi) and Immgolis Intri (golimumab-sldi), first biosimilars to Simponi (golimumab) and Simponi Aria (golimumab)
18 May 2026 - Accord BioPharma announced today that the US FDA has approved Immgolis (golimumab-sldi), a biosimilar to Simponi (golimumab), for the treatment of adult patients with moderately to severely active rheumatoid arthritis in combination with methotrexate, and adult patients with moderately to severely active ulcerative colitis.
The FDA also approved Immgolis Intri (golimumab-sldi), a biosimilar to Simponi Aria (golimumab), for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.
